enGene Holdings Inc. Prices Public Offering at $8.50 per Share

By Tamara Parker • Saturday, November 15 15:27 • Permanent Link

Engene Holdings Inc. (NASDAQ: ENGN) has successfully priced its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at an offering price of $8.4999 per pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $130 million.

The company has granted the underwriters a 30-day option to purchase up to 2,294,117 additional common shares at the public offering price, less underwriting discounts and commissions. The offering is anticipated to close on or about November 14, 2025, subject to customary closing conditions.

Jefferies, Leerink Partners, and Wells Fargo Securities are acting as joint book running managers for the offering, while Raymond James and Van Lanschot Kempen are serving as co-lead managers, and H.C. Wainwright & Co. is acting as co-manager.

Engene is a clinical-stage biotechnology company focused on delivering therapeutics to mucosal tissues and other organs to address diseases with high clinical needs. The company's lead program, detalimogene voraplasmid, is being evaluated in the ongoing multi-cohort legend phase 2 trial for patients with non-muscle invasive bladder cancer. This program is developed using Engene’s proprietary dually derivatized oligochitosan platform, enabling the delivery of various cargo, including DNA and different forms of RNA.

The securities offered by Engene are pursuant to its effective shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on November 13, 2024, and declared effective on November 21, 2024.

This successful pricing of the public offering indicates a significant milestone for Engene as it seeks to advance its genetic medicine delivery platform and support the development of therapies for diseases with high clinical needs. As a result of these announcements, the company's shares have moved 1.19% on the market, and are now trading at a price of $8.53. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.